BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 7590863)

  • 1. Serum nitrite plus nitrate in infection with human immunodeficiency virus type-1.
    Zangerle R; Fuchs D; Reibnegger G; Werner-Felmayer G; Gallati H; Wachter H; Werner ER
    Immunobiology; 1995 Jun; 193(1):59-70. PubMed ID: 7590863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.
    Fahey JL; Taylor JM; Detels R; Hofmann B; Melmed R; Nishanian P; Giorgi JV
    N Engl J Med; 1990 Jan; 322(3):166-72. PubMed ID: 1967191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma levels of viro-immunological markers in HIV-infected and non-infected Ethiopians: correlation with cell surface activation markers.
    Messele T; Brouwer M; Girma M; Fontanet AL; Miedema F; Hamann D; Rinke de Wit TF
    Clin Immunol; 2001 Feb; 98(2):212-9. PubMed ID: 11161977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta-2-microglobulin, neopterin and monocyte Fc gamma receptors in opportunistic infections of HIV-positive patients.
    Dunne J; Feighery C; Whelan A
    Br J Biomed Sci; 1996 Dec; 53(4):263-9. PubMed ID: 9069103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection.
    Godfried MH; van der Poll T; Mulder JW; Weverling GJ; Endert E; Lange JM; Sauerwein HP
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(5):531-9. PubMed ID: 8548332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Lymphocyte subpopulations, neopterin, and beta-2-microglobulin: relationship with clinical stage, risk of progression to AIDS and presence of active infection in HIV infection].
    Antón F; Labarga P; Pinilla J; Soto MJ; Leoz A; del Cura J; Borque L; Milazzo A
    Enferm Infecc Microbiol Clin; 1993; 11(7):373-7. PubMed ID: 8104488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased concentrations of soluble tumor necrosis factor receptor 75 but not of soluble intercellular adhesion molecule-1 are associated with the decline of CD4+ lymphocytes in HIV infection.
    Zangerle R; Fuchs D; Sarcletti M; Gallati H; Reibnegger G; Wachter H; Dierich MP; Möst J
    Clin Immunol Immunopathol; 1994 Sep; 72(3):328-34. PubMed ID: 7914841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of serum beta 2-microglobulin in HIV infection.
    Krämer A; Goedert JJ; Wachter H; Fuchs D
    Lancet; 1992 Aug; 340(8815):371. PubMed ID: 1379663
    [No Abstract]   [Full Text] [Related]  

  • 9. [Serum neopterin and beta2-microglobulin concentration as "prognostic markers" of AIDS].
    Halota W; Jaruga B; Pawłowska M
    Pol Merkur Lekarski; 2002 Aug; 13(74):126-8. PubMed ID: 12420343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased serum concentrations of soluble tumor necrosis factor receptors in HIV-infected individuals are associated with immune activation.
    Zangerle R; Gallati H; Sarcletti M; Weiss G; Denz H; Wachter H; Fuchs D
    J Acquir Immune Defic Syndr (1988); 1994 Jan; 7(1):79-85. PubMed ID: 7903382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor necrosis factor alpha and soluble tumor necrosis factor receptors in individuals with human immunodeficiency virus infection.
    Zangerle R; Gallati H; Sarcletti M; Wachter H; Fuchs D
    Immunol Lett; 1994 Jul; 41(2-3):229-34. PubMed ID: 8002043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Serum adenosine deaminase in human immunodeficiency virus infection. Its relationship with CD4+ lymphocytes and beta 2-microglobulin].
    Iñigo MA; Ruiz López de Tejada M; Torres-Tortosa M; Sánchez-Porto A; Ugarte I; García de Lomas E; Morán Nestares A
    Med Clin (Barc); 1992 Dec; 99(20):766-8. PubMed ID: 1361013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.
    Dis Markers; 1990; 8(3):164-5. PubMed ID: 2125538
    [No Abstract]   [Full Text] [Related]  

  • 14. Stability of plasma levels of cytokines and soluble activation markers in patients with human immunodeficiency virus infection.
    Aziz N; Nishanian P; Taylor JM; Mitsuyasu RT; Jacobson JM; Dezube BJ; Lederman MM; Detels R; Fahey JL
    J Infect Dis; 1999 Apr; 179(4):843-8. PubMed ID: 10068579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased levels of serum intercellular adhesion molecule 1 in HIV infection are related to immune activation.
    Diez-Ruiz A; Kaiser G; Jäger H; Birkmann J; Tilz GP; Wachter H; Fuchs D
    Int Arch Allergy Immunol; 1993; 102(1):56-60. PubMed ID: 8104576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2',5'-oligoadenylate synthetase, neopterin and beta 2-microglobulin in asymptomatic HIV-infected individuals.
    Witt PL; Spear GT; Lindstrom MJ; Kessler HA; Borden EC; Phair J; Landay AL
    AIDS; 1991 Mar; 5(3):289-93. PubMed ID: 2059368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Markers of risk in HIV-1.
    Krämer A; Biggar RJ; Goedert JJ
    N Engl J Med; 1990 Jun; 322(26):1886. PubMed ID: 1971915
    [No Abstract]   [Full Text] [Related]  

  • 18. Nitric oxide formation as predictive parameter for acute graft-versus-host disease after human allogeneic bone marrow transplantation.
    Weiss G; Schwaighofer H; Herold M; Nachbaur D; Wachter H; Niederwieser D; Werner ER
    Transplantation; 1995 Dec; 60(11):1239-44. PubMed ID: 8525517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation.
    Zangerle R; Sarcletti M; Gallati H; Reibnegger G; Wachter H; Fuchs D
    J Acquir Immune Defic Syndr (1988); 1994 Nov; 7(11):1149-56. PubMed ID: 7932082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behaviour of different clinical, immunological and serological parameters observed in a group of HIV positive patients during a 12 month treatment period with zidovudine.
    Crocchiolo PR; Lizioli A; Arcidiacono I; Cantaluppi P; Filippi C; Sobatti D; Bedarida G; D'Agostino F; Cambie G; Nardella ML
    Boll Ist Sieroter Milan; 1990 Jun; 69(2):423-30. PubMed ID: 1983798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.